Puma Biotechnology, Inc. revenue
Puma Biotechnology, Inc.'s revenue was $228m in fiscal 2025, down 0.9% on the year before. Since fiscal 2017 ($27.7m) it has grown at a compound 30.2% a year. Over the last twelve months it was $231m.
Revenue history
| Fiscal year | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28 | 251 | 272 | 225 | 253 | 228 | 236 | 230 | 228 | 231 |
| Growth on the year before | — | +806.6% | +8.5% | −17.3% | +12.5% | −9.9% | +3.3% | −2.2% | −0.9% | — |
| Gross profit | 22 | 216 | 235 | 186 | 189 | 173 | 173 | 166 | 170 | 173 |
| Gross margin | 79.9% | 86.2% | 86.5% | 82.5% | 74.8% | 75.8% | 73.4% | 72.1% | 74.5% | 74.8% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $204M | 89.4% | ▲ 4.6% |
| Royalty | $24.3M | 10.6% | ▼ 31.1% |
From Puma Biotechnology, Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Puma Biotechnology, Inc. | $231m | -2.9% | 0.2% |
| Ideaya Biosciences, Inc. | $234m | -70.1% | 94.0% |
| Anaptysbio, Inc | $238m | 92.9% | 163.9% |
| Rhythm Pharmaceuticals, Inc. | $240m | 53.5% | 76.3% |
| Akebia Therapeutics, Inc. | $219m | 7.5% | 2.9% |
| Ligand Pharmaceuticals Inc | $254m | 1.0% | 18.2% |
Compare with peers
- Ideaya Biosciences, Inc. revenue
- Anaptysbio, Inc revenue
- Rhythm Pharmaceuticals, Inc. revenue
- Akebia Therapeutics, Inc. revenue
- Ligand Pharmaceuticals Inc revenue
Head to head: IDYA vs PBYIANAB vs PBYIPBYI vs RYTMAKBA vs PBYI
More: Biotechnology stocks compared, Health Care sector, rankings of US companies